Tinted IOL demonstrates no significant changes in contrast and sensitivity

Article

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception.

Using an ultraviolet (UV) and blue-light filtering IOL presents no significant changes in scotopic and photopic contrast sensitivity, and colour perception, according to a study published in the Journal of Cataract and Refractive Surgery.

A prospective, randomized clinical study led by Dr Marcony R. Santhiago, Ophthalmology Department, University of São Paulo, Brazil, consisted of 60 eyes of 30 patients with bilateral visually significant cataract.

Each patient was fitted with a UV and blue-light filtering IOL in one eye (Acrysof Natural SN60AT) and a UV-only IOL (Acrysof SA60AT) in the fellow eye. The primary outcome measures included scotopic and photopic contrast sensitivity, colour vision and macular findings. All measurements were taken 5 years postoperatively.

The results demonstrated no significant optical coherence tomography (OCT) findings with regards to age-related macular degeneration. Also, there were no significant differences between the groups in terms of photopic and scotopic contrast sensitivity.

Additional studies are required to identify the potential advantages of using tinted IOLs for the protection of macular cells.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.